Cisplatin-resistant A549 non-small cell lung cancer cells can be identified by increased mitochondrial mass and are sensitive to pemetrexed treatment

BACKGROUND: Cisplatin plus pemetrexed combination therapy is considered the standard treatment for patients with advanced, non-squamous, non-small-cell lung cancer (NSCLC). However, advanced NSCLC has a 5-year survival rate of below 10%, which is mainly due to therapy resistance. We previously showe...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Cancer Cell Int
Main Authors: Gao, Yanyun, Dorn, Patrick, Liu, Shengchen, Deng, Haibin, Hall, Sean R. R., Peng, Ren-Wang, Schmid, Ralph A., Marti, Thomas M.
Formato: Artigo
Idioma:Inglês
Publicado: BioMed Central 2019
Assuntos:
Primary Research
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6883680/
https://ncbi.nlm.nih.gov/pubmed/31798346
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12935-019-1037-1
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares